22nd Century Group (XXII) Stock Forecast and Price Target (2026)

Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with XXII. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.

With continuing losses, earnings multiples do not apply, and the per-share figures Yahoo Finance reports are distorted by the reverse splits and the jump in share count. What matters is cash runway (~$6.1 million against a quarterly operating loss of ~$3.3 million), the pace of dilution, a share price back below Nasdaq's $1 minimum, and whether the FDA reduced-nicotine standard advances. All figures should be checked against the latest SEC filings, since financings can change the share count dramatically between them.

No analyst publishes estimates on XXII, so these are the most recent figures we hold, as of October 2026. They describe where the company stands, not where it is going.

• Revenue: ~$17.6 million in 2025; Q2 2026 ~$2.9 million, down ~30% YoY (VLN ~$0.03 million of it)
• Profitability: Q2 2026 gross loss ~$0.3 million, operating loss ~$3.3 million, adjusted EBITDA loss ~$3.5 million
• Net loss to common (Q2 2026): ~$21.8 million, including ~$17.5 million of deemed dividends on preferred financings
• Balance sheet: cash ~$6.1 million at June 30, 2026 (from ~$7.1 million at year-end 2025); ~$1.1 million of notes and loans
• Share count: 502,839 shares at June 30, 2026, up from 25,709 at year-end 2025
• Stock and market value: ~$0.40 on October 16, 2026; down ~99.9% over 1 year (split-adjusted); market value under ~$300,000
• Next report: Q3 2026 results scheduled for November 3, 2026

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering XXII do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether 22nd Century Group can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are FDA reduced-nicotine rule as the core catalyst, VLN commercialization and state-by-state expansion, Contract manufacturing and plant-science assets. The risk cited most often against it is the risks here are severe and central to the story.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the XXII is it a buy page. This page deliberately stops at the numbers.